Disease Overview：Pulmonary Vasculitis（PV）
Pulmonary vasculitis refers to a group of systemic autoimmune disorders characterized by inflammation and necrosis of blood vessel walls within the lungs—commonly involving small- to medium-sized arteries, arterioles, capillaries, and venules. Key subtypes include granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), microscopic polyangiitis (MPA), and Behçet’s disease-associated pulmonary vasculitis. Clinical manifestations range from cough, hemoptysis, and dyspnea to life-threatening alveolar hemorrhage or progressive pulmonary fibrosis. Diagnosis relies on integrated assessment: high-resolution CT chest imaging, bronchoalveolar lavage, serologic testing (e.g., ANCA titers), and often surgical lung biopsy. Early, accurate diagnosis and immunosuppressive therapy—including glucocorticoids, cyclophosphamide, rituximab, or newer biologics—are critical to prevent irreversible lung damage and mortality.
China offers distinct advantages for pulmonary vasculitis management: its leading respiratory centers—such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital—host nationally recognized vasculitis specialty units with extensive experience in rare autoimmune lung diseases. Advanced diagnostics (e.g., digital pathology, multiplex ANCA testing) and access to FDA- and NMPA-approved biologics are standard. Five-year remission rates exceed 75% in recent cohort studies, with low relapse incidence under structured maintenance protocols. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising clinical rigor or outcomes. As a dedicated medical tourism agency, we facilitate seamless international patient journeys—vetting accredited hospitals, coordinating multidisciplinary consultations, providing itemized, transparent pricing in advance, and offering end-to-end support including visa assistance, interpreter services, and post-treatment follow-up coordination.
Pulmonary Vasculitis: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Pulmonary Vasculitis (Respiratory Medicine)
Non-Surgical / Medical Management
*Target Criteria:* Confirmed diagnosis (e.g., GPA, MPA, EGPA) with active disease (elevated ANCA, CRP, hemoptysis, pulmonary infiltrates, declining DLCO), no life-threatening organ failure.
- •Induction Therapy (3–6 months)
- *Cyclophosphamide IV (750 mg/m² monthly × 3–6 months)*: $420–$580 - *High-dose oral pred/day tapering)*: $15–$25 - *Supportive meds (PJP prophylaxis,itamin D)*: $60–$90
- •Maintenance Therapy (≥12 months)ituximab (500 mg IV every 6 months)*: $920–$1,100/dose
- *Low-dose prednisone (≤5 mg/day)*: $5
- •Diagnostic & Monitoring Labs/Exams (per cycle)
- Chest HRCT:
$140–$180 -FT) + DLCO: $75 - Serum creatinine, CRP, ESR, LFTs,5 - Bronchoscopy with BAL (if hemoptysis/infiltrates): $410Surgical / Interventional Procedures
*Eligibility Criteria:* Refractory alveolar hemorrhage un high-dose steroids + rituximab/cyclophosphamide; massive hemoptysis with hemodynamicary necrosis with infection or hemorrhage risk.
- •Bronchial Artery Embolization (BAE)
- Procedure session): $1,950–$2,450 - Bilateral or repeat BAE (within 30 days): $3,100–$3,800
- •Lung Resection (W - Pre-op: Full pulmonary workup (HRCT, PFT, V/Q scan, cardiac echo): $58S-assisted resection (1 lesion): $4,200–$5,300
Special/Complex Condition Management
- •Plasma Exchange (PLEX) for RPGN or severe DAH: 7 sessions (1.2× PV/session): $3,900–$4,700
- •IVIG (for EGPA refractory to standard therapy): 2 g/kg over 5 days: $2,600–$3,100
- •Biologic escalation (Belimumab or Avacopan adjunct): Monthly IV/subcutaneous: $1,450–$1,800/dose
Quick Selection Guide
- •Young adult (<45), moderate severity, no renal involvement: Rituximab induction + azathioprine maintenance (~$3,200 first year).
- •Elderly (>70) or comorbid (CKD, diabetes): Lower-dose cyclophosphamide + rapid steroid taper + PLEX if DAH (~$4,100 first year).
- •Budget-constrained (<$2,500/year): Azathioprine + prednisone + rigorous monitoring (~$1,900 first
- •Life-threatening DAH or RPGN: Immediate PLEX + rituximab + high-dose steroids (~$6,800 first 3 months).
- •Recurrent hemoptysis post-medical therapy: BAE ($2,150–$3,800**) before considering resection.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Pulmonary Vasculitis Medical Vacation Packages
Curated transparent all-inclusive packages combining Pulmonary Vasculitis treatment with China top medical destinations:
